Q-linea ABCHIX:QLINES 68 PS Ratio is 1,561.59 as of Jul. 05, 2026, which is 1031% above its 10-year median of 138.10. GuruFocus rates CHIX:QLINES with a GF Score™ of 68/100 and a GF Value™ of kr1,981.69. The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Q-linea AB ranks worse than 88.82% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Q-linea AB's share price is kr1610.00.
Q-linea AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.03. Hence, Q-linea AB's PS Ratio for today is 1,561.59.
The historical rank and industry rank for Q-linea AB's PS Ratio or its related term are showing as below:
CHIX:QLINEs'
s PS Ratio Range Over the Past 10 Years
Min: 8.52 Med: 138.1 Max: 61403.38
Current: 16.34
During the past 11 years, Q-linea AB's highest PS Ratio was 61403.38. The lowest was 8.52. And the median was 138.10.
CHIX:QLINEs's PS Ratio is ranked worse than 88.82% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs CHIX:QLINEs: 16.34
Q-linea AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Q-linea AB was -60.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -69.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -22.40% per year.
During the past 11 years, Q-linea AB's highest 3-Year average Revenue per Share Growth Rate was 132.90% per year. The lowest was -69.40% per year. And the median was 65.10% per year.
Back to Basics: PS Ratio
Q-linea AB (CHIX:QLINEs) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Q-linea AB PS Ratio Related Terms
Q-linea AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Q-linea AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Q-linea AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Q-linea AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Q-linea AB's Share Price of today is kr1610.00. Q-linea AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Q-linea AB (CHIX:QLINES) has a PS Ratio of 1,561.59 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Q-linea AB and its competitors. This is 1031% above median its historical median of 138.10. Over the past decade, Q-linea AB's PS Ratio has ranged from 8.52 to 61,403.38. According to the industry distribution chart, Q-linea AB ranks #715 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 88.8%.
Is Q-linea AB's PS Ratio too high?
Q-linea AB's current PS Ratio of 1,561.59 is 1031% above median its 10-year median of 138.10. Over the past 10 years, this metric has ranged from a low of 8.52 to a high of 61,403.38. The Medical Devices & Instruments industry median PS Ratio is 2.94. Q-linea AB's value of 1,561.59 is 53015.3% above this industry median. Based on the distribution chart, Q-linea AB ranks #715 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #715 out of 805 companies for PS Ratio. This places Q-linea AB in the lower half of its industry. The industry median PS Ratio is 2.94. Q-linea AB's value of 1,561.59 is 53015.3% above this benchmark. Historically, Q-linea AB's own PS Ratio has ranged from 8.52 to 61,403.38 over the past decade. While the company's 10-year median is 138.10 vs. the industry median of 2.94, Q-linea AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current PS Ratio of 1,561.59 is 53015.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current PS Ratio is 1,561.59, which is 1031% above median its own 10-year median of 138.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current PS Ratio of 1,561.59. The stock's GF Value™ is kr1,981.69, compared to a current price of kr1,610.00 — trading 18.8% below its estimated fair value. The current PS Ratio is 1,561.59, which is 1031% above median its 10-year median of 138.10 and 53015.3% above the Medical Devices & Instruments industry median of 2.94. Q-linea AB's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current PS Ratio is 1,561.59 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 18.8% below its estimated GF Value™ of kr1,981.69.
Key valuation signals for CHIX:QLINES:
PS Ratio: 1,561.59 (1031% above median its 10-year median of 138.10)
GF Value™: kr1,981.69 vs. price of kr1,610.00 (18.8% below fair value)
Industry Position: 53015.3% above the Medical Devices & Instruments median (#715 of 805)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
68GF Score
Get the complete analysis for CHIX:QLINES
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
